Solid Biosciences Inc

NASDAQ:SLDB   4:00:00 PM EDT
6.77
+0.12 (+1.80%)
4:13:22 PM EDT: $6.82 +0.05 (+0.74%)
Earnings Announcements

Solid Biosciences Ends Third Quarter With About $142.2 Million In Cash

Published: 11/10/2022 13:11 GMT
Solid Biosciences Inc (SLDB) - Company Ends Q3 With Approximately $142.2 Million in Cash and Investments; Anticipated Cash Runway Into Q2 2024.
Ends Q3 With Approximately $142.2 Million in Cash and Investments; Anticipated Cash Runway Into Q2 2024.
Solid Biosciences - on Track for Anticipated Mid-2023 Ind Submission for Sgt-003, Pending Ind Acceptance, First Patient Dosing in Late-2023.
Net Loss for Q3 of 2022 Was $20.4 Million Versus $18.0 Million.
Solid Biosciences - Expects to Close Acquisition of Aavantibio and $75 Million Private Placement by Year-end.
Q3 Earnings per Share View $-2.67 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.3 Million
Adjusted EPS is expected to be -$2.22

Next Quarter Revenue Guidance is expected to be $2.2 Million
Next Quarter EPS Guidance is expected to be -$1.19

More details on our Analysts Page.